Vitamin C neglect in hemodialysis: sailing between Scylla and Charybdis.
In our efforts to meet the vitamin C requirements of dialysis patients we confront a medical dilemma--do we allow the patient to become depleted of vitamin C, with the accompanying hematological and other consequences (Scylla), or do we provide for adequate tissue levels of vitamin C, which has been thought to carry the risk of oxalosis (Charybdis). Many practitioners are certain that either one outcome (deficiency) or the other (oxalic acid toxicity) is inevitable, and much like Odysseus, no safe course is to be found. The recent accumulating evidence that vitamin C improves the management of anemia in dialysis patients compels us to find a safe passage through this dilemma. The serious vitamin C deficiency seen in many patients may also contribute to poor oral health and chronic fatigue. The evidence for oxalosis from vitamin C supplements stems from hemodialysis as practiced 20 years ago. Investigators using this therapy are not observing systemic oxalosis, and the most current data support the conclusion that vitamin C therapy is safe for dialysis patients. The question will be resolved by controlled trials that address both vitamin C effectiveness and safety.
Handelman
Garry J
GJ
Renal Research Institute, 207 E. 94th Street, New York, NY 10128, USA. ghandelman@rriny.com
D000975:Antioxidants / Q000378:metabolism / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000378:metabolism / Q000627:therapeutic use*; D001206:Ascorbic Acid Deficiency / Q000188:drug therapy / Q000517:prevention & control*; D004920:Erythropoiesis / Q000187:drug effects; D005221:Fatigue; D006801:Humans; D006959:Hyperoxaluria / Q000517:prevention & control*; D009909:Oral Health; D010070:Oxalates / Q000009:adverse effects* / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects*
D000975:Antioxidants; D010070:Oxalates; D001205:Ascorbic Acid